
Dechra has completed its acquisition of Gallant Pet Inc, a US-based animal health biotechnology company developing regenerative medicine therapies for pets.
The acquisition expands Dechra’s veterinary healthcare portfolio into regenerative medicine.
Gallant specialises in ready-to-use mesenchymal stromal cell (MSC) therapies, designed to work with the body’s natural biological processes. Its pipeline targets chronic and complex conditions in pets and aims to provide treatment options beyond conventional symptom management.
According to the company, the acquisition combines its expertise in specialty animal health, global reach and established veterinary relationships with Gallant’s scientific research and regenerative medicine platform. Both the companies expect this new therapeutic platform to support the development of multiple therapies for different conditions and animal species.
Dr Cathy Knupp, Chief Scientific Officer at Dechra, said, “By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant’s scientific innovation and regenerative medicine platform, we’re creating a strong foundation to bring new treatment options to veterinarians and their patients.”
“Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need,” said Dr. Linda Black, CEO of Gallant.
Dechra expects the first innovation from Gallant’s pipeline as early as 2027. Both companies have finalised the transaction, but have agreed to keep its financial terms confidential.




































